Advertisement
Screener

Grace Therapeutics, Inc. (GRCE) Beta

Grace Therapeutics, Inc. (GRCE) Beta

  • Beta · 5-year monthly: Value 0.46; Formula and calculation Saved five-year monthly beta; measures historical sensitivity to the benchmark..

Beta

Overview →

Financial period ending 2026-08-31; current quote 2026-08-31. Amounts retain their stated periods and units.

MetricValueFormula and calculation
Beta · 5-year monthly0.46Saved five-year monthly beta; measures historical sensitivity to the benchmark.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingBeta
2026-08-310.46

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
VERU INC. (VERU)United States$0.043B-3.93
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98